A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

Stopped Upon reviewing current available combo studies, the sponsor decided to prioritize different combo study.

Conditions

• Advanced or Metastatic Solid Tumors
• Non-Small Cell Lung Cancer

Interventions

• DRUG: NC318
• DRUG: Pemetrexed/Carboplatin
• DRUG: Nab paclitaxel/Carboplatin
• DRUG: Docetaxel

Sponsor

NextCure, Inc.